BOSTON, Oct. 17,
2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.
(Nasdaq: NRBO), a clinical-stage biotechnology company on a quest
to transform cardiometabolic diseases, today
announced that Hyung Heon Kim, President and Chief
Executive Officer, and Robert
Homolka, Senior Vice-President of Clinical Operations, will
present a company overview at the H.C. Wainwright 7th
Annual NASH Investor Conference on Tuesday,
October 24th at 2:30 pm
ET.
Mr. Kim and Mr. Homolka will also be available for virtual
one-on-one meetings during the event. Institutional investors who
are registered for the conference can request a meeting through the
conference platform.
A live webcast of Mr. Kim's and Mr. Homolka's presentation will
be available on the Event Calendar page of the NeuroBo website at:
https://www.neurobopharma.com/events-presentations/event-calendar.
An archived replay will be available on the company's website for a
period of 90 days after the conference.
About NeuroBo Pharmaceuticals
NeuroBo
Pharmaceuticals, Inc. is a clinical-stage biotechnology
company on a quest to transform cardiometabolic
diseases. The company is currently developing DA-1241 for the
treatment of Non-Alcoholic Steatohepatitis (NASH) and
Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the
treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor
119 (GPR119) agonist, which promotes the release of
key gut peptides GLP-1, GIP, and PYY. In
preclinical studies, DA-1241 demonstrated positive effect on liver
inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic
inflammation, and liver fibrosis, while also improving glucose
control. DA-1726 is a novel oxyntomodulin
(OXM) analogue that acts as a
glucagon-like peptide-1 receptor (GLP1R) and glucagon
receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut
hormone that activates GLP1R and GCGR, thereby
decreasing food intake while increasing energy expenditure, thus
potentially resulting in superior body weight loss compared to
selective GLP1R agonists. For more information, please
visit www.neurobopharma.com.
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-to-present-at-the-hc-wainwright-7th-annual-nash-investor-conference-301958428.html
SOURCE NeuroBo Pharmaceuticals, Inc.